We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

By LabMedica International staff writers
Posted on 07 Jul 2025

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. More...

Unlike osteoarthritis, which is caused by wear and tear, RA can strike suddenly and is most common in people aged 40-60. The disease is often difficult to treat due to the variation in patients' responses to therapies, with biological therapies offering the best treatment options. However, there is no diagnostic test that can predict which therapy will work for a specific patient. As a result, many patients endure multiple rounds of failed treatments, each carrying the risk of severe side effects and infections due to the suppression of the immune system. New research has identified a way to predict which therapies are most likely to succeed for individual patients, thereby minimizing ineffective treatments and improving patient outcomes.

This breakthrough solution was developed by scientists at Queen Mary University of London (London, UK) by combining deep molecular phenotyping and machine learning to predict patient responses to biological therapies for RA. By extracting RNA from a biopsy taken from an affected joint, they measure the activity of 524 specific genes. This data is then analyzed using machine learning models designed to predict the likelihood of success for three main biological therapies: etanercept, tocilizumab, and rituximab. The approach aims to enable clinicians to select the most effective treatment from the start, reducing the chances of adverse effects and unnecessary treatments.

The research was tested in clinical trials, with results showing that the predictive models accurately forecasted patient responses for 79%-85% of patients. Published in Nature Communications, the findings suggest that this method could significantly improve patient well-being by guiding clinicians toward the most suitable therapy faster. The researchers are in discussions with commercial partners to help bring this predictive tool to clinical practice and are conducting large, randomized controlled trials to further refine the technology. With a clinical trial underway, the team is on course to be the first to introduce a predictive test into a real-world medical setting. Their new approach could revolutionize the way RA treatments are personalized, providing patients with better outcomes and a more efficient healthcare system.  

“This innovation could have major benefits for patients and healthcare providers alike,” said Prof Costantino Pitzalis, Professor of Rheumatology at Queen Mary University of London. “Prescribing the right treatment first time would reduce patient suffering and make our healthcare system more efficient.”

Related Links:
Queen Mary University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.